{"entity":{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","aka":["TARGET-TNBC"],"tldr":"A phase 1/2 trial of zimberelimab and sacituzumab govitecan in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","summary":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases. ClinicalTrials.gov record last updated 2025-12-05: recruiting. Enrollment is planned at 31 participants. Primary completion is estimated at 2027-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan. Registered primary measures: Phase I: Neurologic Toxicity; Phase II: Progression Free Survival (PFS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06238921","url":"https://clinicaltrials.gov/study/NCT06238921"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic","brain-metastases"],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":["zimberelimab","sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-12-05: recruiting. Enrollment is planned at 31 participants. Primary completion is estimated at 2027-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06238921","phase":"1/2","setting":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","participation":[{"nct":"NCT06238921","source":"https://clinicaltrials.gov/study/NCT06238921","fetchedAt":"2026-10-07T16:54:23.000Z","studySha256":"e173e01ff0585eac3969db0a9b7895e5da4bd380924a4112c965ad27c908e082","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-05","leadSponsor":"H. Lee Moffitt Cancer Center and Research Institute","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":31,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2024-12-19","startedType":"actual","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06238921/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}]}}